CGCABLE
834639
KLT
831689
DAYU BIOLOGICAL
871970
4
Fujian Superpipe
300198
5
WuHan Hvsen Biotechnology
300871
US Stock MarketDetailed Quotes
BIOA BioAge Labs
- 3.970
- -0.310-7.25%
Trading Mar 26 12:59 ET
142.32MMarket Cap-2.00P/E (TTM)
4.300High3.960Low195.01KVolume4.300Open4.280Pre Close792.04KTurnover1.86%Turnover RatioLossP/E (Static)35.85MShares26.62052wk High0.44P/B41.68MFloat Cap3.85052wk Low--Dividend TTM10.50MShs Float26.620Historical High--Div YieldTTM7.94%Amplitude3.850Historical Low4.061Avg Price1Lot Size
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
BioAge Labs Stock Forum
Eisai Reveals Ambitious JPY 280B Sales Target for Alzheimer's Drug Leqembi
BioAge Labs Lands Massive $550M Novartis Deal Despite Clinical Setback in 2024 Results
BioArctic Secures Crucial FDA Designation for Rare Fatal Disease Treatment
Exidavnemab is being developed as a disease-modifying treatment for synucleinopathies including MSA and Parkinson's disease. As a monoclonal antib...
BioArctic Leaders Secure Major Innovation Award as Alzheimer's Drug Conquers Global Markets
BioArctic's Alzheimer's Drug Clears Critical EU Regulatory Hurdle After Safety Evaluation
Alzheimer's Drug Deal: How BioArctic's $1.3B Bristol Myers Agreement Could Transform Treatment
BioArctic AB announced the completion of its global license agreement with Bristol Myers Squibb after receiving U.S. Federal Trade Commission clearance. The agreement, initially announced on December 19, 2024, grants Bristol Myers Squibb worldwide development and commercialization rights for BAN1503 and BAN2803, part ...
Milestone Achievement: Alzheimer's Breakthrough Leqembi Reaches €200M Sales, Triggering Major Payout
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
No comment yet